Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

38.00 +0.95 (+2.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting
From Guardant Health, Inc.
Via Business Wire
Guardant Health, Evolent Health, Charles River Laboratories, Avantor, and Lumen Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the major indices pulled back (Nasdaq -1.3%, S&P 500 - 1.4%) as Treasury yields rose, reflecting market anxiety over a draft federal budget that... 
Via StockStory
Topics Bonds Stocks
Exposures Debt Markets US Equities
Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors
From Guardant Health, Inc.
Via Business Wire
Earnings Scheduled For April 30, 2025
Via Benzinga
Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health: A Promising Player in the Liquid Biopsy Market
Via The Motley Fool
GH Q1 Earnings Call: Guardant Health Lifts Full-Year Guidance Following Oncology and Screening Momentum
Diagnostics company Guardant Health (NASDAQ:GH) announced better-than-expected revenue in Q1 CY2025, with sales up 20.8% year on year to $203.5 million. The company’s full-year revenue guidance of $885... 
Via StockStory
2 Volatile Stocks Worth Investigating and 1 to Steer Clear Of
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor... 
Via StockStory
Topics Stocks
Exposures US Equities
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
Netflix, CNA Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Cathie Wood Pours $9.8 Million In Robinhood Despite Crypto Revenue Slump, Keeps Dumping Palantir Ahead Of Earnings
Cathie Wood's Ark Invest Makes Bold $9.8M Robinhood Bet While Dumping Palantir Ahead of Earnings. 
Via Benzinga
Guardant Health’s (NASDAQ:GH) Q1: Strong Sales, Stock Soars
Diagnostics company Guardant Health (NASDAQ:GH) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 20.8% year on year to $203.5 million. The company’s full-year revenue... 
Via StockStory
Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
Guardant Health Presents Data Demonstrating Strong Performance of Shield Multi-Cancer Detection Test Across 10 Tumor Types
From Guardant Health, Inc.
Via Business Wire
Guardant Health (GH) Q1 Earnings Report Preview: What To Look For
Diagnostics company Guardant Health (NASDAQ:GH) will be reporting earnings tomorrow after market hours. Here’s what you need to know. 
Via StockStory
Topics World Trade
Exposures Tariff
Pfizer Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Via Benzinga
CORRECTING and REPLACING Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health, Pfizer Collaborate To Develop New Cancer Therapies Using Liquid Biopsy Platform
Guardant Health partners with Pfizer to support oncology drug development using smart liquid biopsy tech and expand testing access in China. 
Via Benzinga
Guardant Health Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Present Data Highlighting Advances in Multi-Cancer Detection and Liquid and Tissue Molecular Profiling at AACR
From Guardant Health, Inc.
Via Business Wire
RXO, The Ensign Group, LifeStance Health Group, Surgery Partners, and Guardant Health Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after President Trump criticized the Federal Reserve's approach to interest rate cuts, warning that the pace was slow and could hinder economic growth.... 
Via StockStory
Topics Economy Government World Trade
Exposures Interest Rates Political Tariff
3 Reasons to Sell GH and 1 Stock to Buy Instead
What a time it’s been for Guardant Health. In the past six months alone, the company’s stock price has increased by a massive 112%, reaching $44.11 per share. This run-up might have investors... 
Via StockStory
Topics Bankruptcy
Exposures Financial Legal
3 of Wall Street’s Favorite Stocks Facing Headwinds
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
A revolution in oncology could help cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences. 
Via Investor's Business Daily
Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025
From Guardant Health, Inc.
Via Business Wire
Reflecting On Testing & Diagnostics Services Stocks’ Q4 Earnings: Guardant Health (NASDAQ:GH)
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q4, starting... 
Via StockStory
Testing & Diagnostics Services Stocks Q4 Recap: Benchmarking NeoGenomics (NASDAQ:NEO)
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the testing & diagnostics services stocks, including NeoGenomics (NASDAQ:NEO) and its peers. 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.